Blog
RSS FeedPosted by Michael Wonder on 28 Feb 2022
Amylyx Pharmaceuticals announces EMA validation of marketing authorisation application for AMX0035 for the treatment of ALS
25 February 2022 - Amylyx Pharmaceuticals today announced that its marketing authorisation application to the EMA CHMP for AMX0035 (sodium phenylbutyrate ...
Posted by Michael Wonder on 24 Feb 2022
Cystic fibrosis community disappointed with PTAC recommendations
23 February 2022 - New Zealand’s cystic fibrosis community received disappointing news today with a recommendation to PHARMAC that reduces ...
Posted by Michael Wonder on 24 Feb 2022
Valeo Pharma obtains public reimbursement for Enerzair Breezhaler and Atectura Breezhaler in Ontario, Manitoba and New Brunswick
24 February 2022 - Private insurance coverage across Canada exceeds 90%. ...
Posted by Michael Wonder on 23 Feb 2022
PHARMAC recommends funding cystic fibrosis medicine Trikafta but needs more funding
23 February 2022 - PHARMAC’s clinical experts are recommending cystic fibrosis drug Trikafta be funded for those aged over 12 ...
Posted by Michael Wonder on 23 Feb 2022
PHARMAC’s clinical experts recommend funding Trikafta
23 February 2022 - PHARMAC today announces its clinical advisory committee PTAC has recommended funding cystic fibrosis treatment Trikafta with ...
Posted by Michael Wonder on 15 Feb 2022
‘New hope’: breakthrough cystic fibrosis treatment to be listed on PBS
14 February 2022 - Health Minister Greg Hunt says the breakthrough treatment for cystic fibrosis, Trikafta, will soon be able ...
Posted by Michael Wonder on 12 Feb 2022
China approves use of Pfizer's COVID drug Paxlovid
12 February 2022 - China's medical products regulator said on Saturday it has given conditional approval for Pfizer's COVID-19 drug ...
Posted by Michael Wonder on 01 Feb 2022
'Lifesaving' cystic fibrosis drug Trikafta recommended for inclusion on PBS
1 February 2022 - Thousands of people with cystic fibrosis are one step closer to accessing a 'lifesaving' drug, after ...
Posted by Michael Wonder on 28 Jan 2022
'I feel like I'm drowning': thousands with cystic fibrosis wait to hear if 'life-saving' drug will be listed on PBS
27 January 2022 - Matt Dickinson was struggling to breathe when his mother rushed him to an Adelaide hospital earlier ...
Posted by Michael Wonder on 27 Jan 2022
COVID-19: EMA recommends conditional marketing authorisation for Paxlovid
27 January 2022 - The EMA’s CHMP has recommended granting a conditional marketing authorisation for the oral antiviral medicine Paxlovid ...
Posted by Michael Wonder on 22 Jan 2022
COVID-19: early access granted to Paxlovid as a curative treatment
21 January 2022 - In the context of very high circulation of SARS-CoV-2, the High Authority for Health (HAS) and the ...
Posted by Michael Wonder on 16 Jan 2022
Glenmark receives NDA approval by the United States FDA for Ryaltris nasal spray for the treatment of symptoms of seasonal allergic rhinitis in adults and paediatric patients 12 years of age and older
14 January 2022 - Ryaltris will be marketed and distributed in the United States through its partner Hikma. ...
Posted by Michael Wonder on 11 Jan 2022
European Commission approves Kaftrio (ivacaftor/tezacaftor/elexacaftor) in combination with ivacaftor to treat children with cystic fibrosis ages 6 to 11 years
11 January 2022 - More than 1,500 children now eligible to receive a treatment targeting the underlying cause of cystic ...
Posted by Michael Wonder on 10 Jan 2022
EMA receives application for conditional marketing authorisation for Paxlovid (PF-07321332 and ritonavir) for treating patients with COVID-19
10 January 2022 - EMA has started evaluating an application for a conditional marketing authorisation for the oral antiviral medicine ...
Posted by Michael Wonder on 05 Jan 2022
Amylyx Pharmaceuticals submits marketing authorisation application for AMX0035 for the Treatment of ALS
4 January 2022 - Amylyx Pharmaceuticals today announced it has submitted a marketing authorisation application to the EMA's CHMP for ...